DA-1241, a GPR119 Agonist, Ameliorates Fatty Liver Through the Upregulation of TFEB-Mediated Autophagy
DA-1241 is a novel small-molecule GPR119 agonist. DA-1241 treatment stimulates autophagy induction and transcriptional factor EB (TFEB) nuclear translocation and subsequently reduces hepatic fat accumulation both in vitro and in vivo. DA-1241 treatment increases the lysosomal activity and colocalization of mRFP-LC3 with lipid droplets. The antisteatotic effect of DA-1241 is offset by GPR119 knockdown or in tfeb knockout HeLa cells and liver-specific Tfeb knockout mice.
Authors
- Myung‐Shik Lee (ORCID: https://orcid.org/0000-0003-3292-1720)
- You‐Cheol Hwang (ORCID: https://orcid.org/0000-0003-4033-7874)
- Jin Yoo
- Ho Yeon Chung (ORCID: https://orcid.org/0000-0002-4529-8280)
- In‐Kyung Jeong (ORCID: https://orcid.org/0000-0001-7857-546X)
- Ji Eun Jun (ORCID: https://orcid.org/0000-0002-7204-4913)
- Kyu Jeung Ahn (ORCID: https://orcid.org/0000-0002-4648-3605)
Institutions
- Soonchunhyang University (KR)
- Kyung Hee University (KR)
- Kyung Hee University Hospital at Gangdong (KR)
Publication Details
- Journal
- Diabetes
- Published
- 2025-03-28
- DOI
- https://doi.org/10.2337/db24-0370
- Citations
- 2
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 4.01